.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The development of direct-acting antiviral combinations transformed chronic hepatitis C treatment. Modern regimens achieve sustained virologic response in the overwhelming majority of appropriately selected patients, usually with short oral courses and far fewer adverse effects than historical interferon-based therapy. For internists, the key clinical opportunity is case finding: many infected individuals remain undiagnosed because chronic hepatitis C can be asymptomatic for years. Once infection is confirmed, fibrosis assessment, drug-interaction review and selection of an appropriate pangenotypic regimen can be coordinated with specialist input when required. Cure reduces the risk of progressive liver disease and hepatocellular carcinoma, although patients with established cirrhosis still require ongoing surveillance. The broader public-health lesson is that effective therapy does not eliminate the need for screening and linkage to care. APICON's hepatology track therefore intersects with internal medicine at multiple levels—from recognizing abnormal liver enzymes to managing metabolic and infectious contributors to chronic liver disease.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The development of direct-acting antiviral combinations transformed chronic hepatitis C treatment. Modern regimens achieve sustained virologic response in the overwhelming majority of appropriately selected patients, usually with short oral courses and far fewer adverse effects than historical interferon-based therapy. For internists, the key clinical opportunity is case finding: many infected individuals remain undiagnosed because chronic hepatitis C can be asymptomatic for years. Once infection is confirmed, fibrosis assessment, drug-interaction review and selection of an appropriate pangenotypic regimen can be coordinated with specialist input when required. Cure reduces the risk of progressive liver disease and hepatocellular carcinoma, although patients with established cirrhosis still require ongoing surveillance. The broader public-health lesson is that effective therapy does not eliminate the need for screening and linkage to care. APICON's hepatology track therefore intersects with internal medicine at multiple levels—from recognizing abnormal liver enzymes to managing metabolic and infectious contributors to chronic liver disease.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
